To evaluate the efficacy and safety of Bcl-2 family-based vaccinations the first phase I vaccination study have been started (from June 2010) at Herlev University Hospital, Denmark and Odense University Hospital, Denmark in which multiple myeloma patients are being vaccinated with HLA-restricted Bcl-2, Bcl-X(L) and/or Mcl-1-derived epitopes in connection with Montanide adjuvant (www.clinicaltrials.gov). This evidence concerns the gene BCL2L1 and plasma cell myeloma.